Evidence map›Paper›PMID 31271052›Full record

ArticleCell transplantation

Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.

Dorothy M Supp, Jennifer M Hahn, Kelly A Combs, Kevin L McFarland, Ann Schwentker, Raymond E Boissy, Steven T Boyce, Heather M Powell, Anne W Lucky

Open access · goldAbstract read
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Comparison of biopolymer scaffolds for the fabrication of skin substitutes in a porcine wound model.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. A non-viral and selection-freeMolecular therapy. Nucleic acids · 2021
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dorothy M SuppResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.ORCID 0000-0002-2429-6630
Jennifer M HahnResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.
Kelly A CombsResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.
Kevin L McFarlandResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.
Ann SchwentkerDivision of Plastic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Raymond E BoissyDepartment of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Steven T BoyceResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.
Heather M PowellResearch Department, Shriners Hospitals for Children - Cincinnati, Cincinnati, OH, USA.
Anne W LuckyDivision of Dermatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Shriners Hospitals for Children - Cincinnati · USCincinnati Children's Hospital Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blistering disease recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in the gene encoding collagen VII (COL7), which forms anchoring fibrils that attach the epidermis to the dermis. Cutaneous gene therapy to restore COL7 expression in RDEB patient cells has been proposed, and cultured epithelial autograft containing COL7-modified keratinocytes was previously tested in clinical trials. Because COL7 in normal skin is expressed in both fibroblasts and keratinocytes, cutaneous gene therapy using a bilayer skin substitute may enable faster restoration of anchoring fibrils. Hypothetically, COL7 expression in either dermal fibroblasts or epidermal keratinocytes might be sufficient for functional anchoring fibril formation in a bilayer skin substitute. To test this, engineered skin substitutes (ESS) were prepared using four combinations of normal + RDEB cells: (1) RDEB fibroblasts + RDEB keratinocytes; (2) RDEB fibroblasts + normal keratinocytes; (3) normal fibroblasts + RDEB keratinocytes; and (4) normal fibroblasts + normal keratinocytes. ESS were incubated in vitro for 2 weeks prior to grafting to full-thickness wounds in immunodeficient mice. Biopsies were analyzed in vitro and at 1, 2, or 3 weeks after grafting. COL7 was undetectable in ESS prepared using all RDEB cells (group 1), and macroscopic blistering was observed by 2 weeks after grafting in ESS containing RDEB cells. COL7 was expressed, in vitro and in vivo, in ESS prepared using combinations of normal + RDEB cells (groups 2 and 3) or all normal cells (group 4). However, transmission electron microscopy revealed structurally normal anchoring fibrils, in vitro and by week 2 in vivo, only in ESS prepared using all normal cells (group 4). The results suggest that although COL7 protein is produced in engineered skin when cells in only one layer express the COL7 gene, formation of structurally normal anchoring fibrils appears to require expression of COL7 in both dermal fibroblasts and epidermal keratinocytes.

Indexed as

FibroblastsGene Expression RegulationKeratinocytesSkin, ArtificialTissue EngineeringAdultAnimalsCollagen Type VIIEpidermolysis Bullosa DystrophicaHeterograftsHumansMaleMiceMutationWound HealingWounds and InjuriesCollagen Type VIIanchoring fibrilbasement membranecollagen VIIengineered skin substitutefibroblastkeratinocyterecessive dystrophic epidermolysis bullosa

Identifiers

PMID31271052
PMCPMC6767893
OpenAlexW2954477781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.